Below you'll find a list of all posts that have been tagged as “life sciences”
“Getting closer to stakeholders” is familiar advice, but it rarely tells competitive intelligence leaders what to actually change. Our 2026 Life Sciences CI Survey data pinpoints which factors truly drive senior leadership reach, strategic influence, and stakeholder satisfaction, and a few widely held assumptions don’t survive the analysis.
At Pharma CI USA 2026, AI came up in nearly every conversation, but the bigger story was what leadership now expects from competitive intelligence. Here are the key takeaways on trust in AI, the rising value of primary intelligence, and why CI’s impact is increasingly measured by the decisions it shapes.
AI adoption in life sciences competitive intelligence nearly doubled in a single year. Our 2026 survey data shows where AI is delivering real impact, where friction is growing, and what CI leaders should realistically expect from their investment.
A leading pharmaceutical company needed a validated, continuously updated view of the competitive landscape across lab, point-of-care, and self-test diagnostics. Sedulo’s program combined landscape analysis, ongoing monitoring, and primary intelligence to support confident D2C strategy and expansion decisions.
A leading pharmaceutical company needed a validated, continuously updated view of the competitive landscape across lab, point-of-care, and self-test diagnostics. Sedulo’s program combined landscape analysis, ongoing monitoring, and primary intelligence to support confident D2C strategy and expansion decisions.
A major oncology congress means something very different to a team supporting a Phase 2 asset than it does to a team twelve months from launch. The event is the same. The therapeutic area may be the same. But what the CI function needs to extract from it, what counts as high-priority intelligence, what gets documented with the most care, …
Every major pharmaceutical and biotech company at a medical congress has made a series of deliberate decisions before a single attendee walks through the exhibit hall doors. How large a footprint to take. Where on the floor to position it. What messaging to put on the largest visible surface. Which data to feature. What materials to hand to every HCP …
Most pharma CI teams attend the major congresses. Few are structured to capture everything those congresses offer. This post breaks down the five most common intelligence gaps, and what a well-designed coverage program does to close them.
A pharmaceutical company needed more than a snapshot of competitor sales forces. Sedulo designed a continuous oncology intelligence program that tracked how seven key competitors were structuring, scaling, and deploying commercial resources, delivering the early signals needed to sharpen share-of-voice strategy and commercial planning.
Scientific and medical conferences are among the most intelligence-rich environments in pharma, but most organizations capture only a fraction of what’s available. This guide breaks down what a structured conference coverage program looks like and how to turn congress attendance into actionable competitive intelligence.
